What ≥99% Purity Actually Means: HPLC Explained

High-Performance Liquid Chromatography is the analytical method behind every purity claim in the research peptide category. This article explains what HPLC physically does, how a purity percentage is calculated from a chromatogram, why ≥99% is the working threshold for research-grade material, and what it means in practice when a vendor ships a batch at 98% or lower.

HPLC sits inside a three-method release framework — pairing it with mass spectrometry for identity and LAL or rFC for endotoxin contamination is what makes a complete batch characterization possible, a topic covered in the three core analytical methods. The chromatogram itself is the evidentiary surface a Certificate of Analysis exposes to the reader, which is why reading the COA correctly and reading a chromatogram are paired skills.

What does HPLC physically do?

HPLC separates a mixture by exploiting differences in how each compound interacts with a stationary phase (a packed column) and a mobile phase (a liquid solvent). The sample is injected into a stream of mobile phase, which flows through the column under high pressure. Compounds that interact strongly with the stationary phase travel slowly; weakly interacting compounds travel quickly. By the time the mobile phase exits the column, the compounds have separated in time — they reach the detector at different moments.

The detector — typically UV absorbance at a peptide-relevant wavelength — records the amount of material passing through it as a function of time. The result is a chromatogram: a plot of detector response (y-axis) versus elution time (x-axis), with each compound appearing as a peak at its characteristic retention time.

For peptides, the dominant variant is reverse-phase HPLC (RP-HPLC). The stationary phase is hydrophobic — a C18 alkyl chain bonded to silica is the standard. The mobile phase is a gradient of water and acetonitrile, often modified with trifluoroacetic acid (TFA) to control ionization. Peptides separate primarily by hydrophobicity: more hydrophobic peptides interact more strongly with the C18 column and elute later. The mechanism is thoroughly characterized in USP <621> Chromatography, which sets the system-suitability and reporting criteria the rest of the industry inherits.

How is HPLC purity actually calculated?

On the chromatogram, the target peptide appears as the dominant peak. Smaller peaks at earlier and later retention times represent impurities — synthesis byproducts, oxidation products, residual protecting groups from solid-phase synthesis, truncated sequences, or in some cases the system's baseline noise integrated as small peaks. The math is straightforward: the chromatography software integrates the area under each peak and reports the target peak's area as a percentage of the total integrated area.

Purity (%) = (target peak area / sum of all peak areas) × 100

This is sometimes called "area-normalized purity" or "area %" — different software conventions and different lab reporting standards may label it slightly differently, but the math is the same. A peptide with a target peak that integrates to 99.4% of the total area is reported as ≥99.4% pure. The practical skill of reading a chromatogram visually — what counts as a peak, what counts as baseline noise, what artifacts to ignore — is its own topic, covered in reading the chromatogram visually.

What does HPLC purity not tell you?

A purity percentage is not a complete description of a peptide batch. There are properties the HPLC method, by its nature, cannot detect — and understanding the boundary conditions is part of reading a COA correctly. The table below summarizes what HPLC measures, what it misses, and which complementary method covers the gap.

HPLC tells you how cleanly the target separated

A high purity number means the target compound dominated the chromatogram and the method successfully resolved impurities into their own peaks. The result is precise, reproducible, and meaningful — it tells you the proportion of material in the vial that elutes as the target peak under the specified method.

HPLC does not on its own confirm identity

A peak at the expected retention time is not proof that the peak is the expected compound. Different compounds can have similar retention times under a given method; a 99.9%-pure sample of the wrong peptide is theoretically possible. Identity confirmation requires a separate method — mass spectrometry on the same batch — which is why complete batch testing always pairs HPLC with MS and never relies on either alone.

HPLC does not detect endotoxin or microbial contamination

Endotoxin contamination is invisible to HPLC. A lipopolysaccharide-contaminated peptide can still report 99.9% HPLC purity because endotoxin doesn't absorb at typical peptide-detection wavelengths in the same retention range. Detection requires its own assay — LAL or rFC — and the result should appear on a separate line of the COA. Skipping endotoxin testing and relying only on HPLC is a structural gap in a release protocol.

HPLC does not detect chiral or stereochemical impurities

Standard RP-HPLC cannot distinguish between stereoisomers. If a synthesis produces a peptide with the wrong stereochemistry at one residue (a D-amino acid where an L was intended, for example), the wrong-stereochemistry peptide will often co-elute with the correct one. Detecting stereochemical impurities requires chiral HPLC or alternative methods. For most research peptide products this is not commonly a primary concern, but it is part of why ≥99% purity is a method-bound claim, not an absolute one.

Why is ≥99% the working threshold?

There is no single industry-wide cutoff that defines "research grade" peptide purity. Different laboratories, different research applications, and different regulatory contexts use different thresholds. Empirically, though, ≥99% has emerged as the dominant standard in research-supplier catalogs — a convergence driven by detection limits, the impurity-content step-change between 98% and 99%, and the rise of automated peak-integration software that made sub-1% peaks reliably resolvable in routine production.

Detection limits and method noise

Modern HPLC methods can resolve peaks down to roughly 0.1% area without ambiguity. Below that, what looks like an impurity may actually be baseline noise being integrated as a peak, or a tail of the target peak that the integration software miscategorized. A reported purity of 99.0% means impurities resolvable above the detection threshold sum to about 1.0% — a number that is genuinely measured rather than an artifact.

A purity reported as 99.95% should be read with some caution: it implies the lab is integrating peaks below 0.05%, which is below most methods' reliable resolution. The marginal value of pushing past 99.5% in reported purity is often overstated; what matters more at that point is the chromatogram's shape and the methodology validity.

What sits below 99%

A peptide reported at 98% has, by definition, 2% impurities — twice as much as a 99% sample, ten times as much as a 99.8% sample. Whether that matters depends on the research context: an immunogenicity study is more sensitive to impurity content than a structural-binding study, for example. But 2% is also the rough zone where some specific synthesis byproducts (truncated sequences, oxidized variants) start being consistently present rather than trace, and a side-by-side look at real batches at 99% versus 98% makes the chromatographic difference visible.

Below 95% purity is the territory where the impurity profile starts to dominate — at that point the material is no longer characterized primarily by what it is, but by what else is in it. Reputable suppliers don't ship below 95%, and many won't ship below 98%. Nexara's threshold is ≥99%, and any batch that falls below that is not sold; the operating posture is documented across our quality standards.

The threshold is method-dependent

A purity number is not portable across methods. The same physical material analyzed by two different HPLC methods — different columns, different gradients, different detection wavelengths — can return slightly different purity percentages. A reported ≥99% comes with an implicit "by this method, in this lab, on this date." USP <621> is unambiguous on the point: the methodology section of the report should "include sufficient detail to allow another competent analyst to reproduce the procedure." Without that, the percentage is unanchored.

What are the common impurities in peptide synthesis?

A non-target peak on a chromatogram is not just "an impurity" — it usually has a specific origin in the synthesis process. The common categories repeat consistently across solid-phase peptide synthesis runs.

• Truncated sequences — peptides missing one or more residues, produced when a coupling step in solid-phase synthesis fails. Typically shorter retention time than the target.
• Deletion sequences — peptides missing a residue from the middle of the chain, produced when a coupling step fails on a specific cycle. Can elute close to the target if the missing residue is small or non-hydrophobic.
• Oxidation products — typically methionine, tryptophan, or cysteine residues oxidized during synthesis or storage. Often elutes earlier than the target as the oxidized form is more polar.
• Deamidation products — asparagine or glutamine converted to aspartate or glutamate respectively, particularly under basic conditions or extended storage. Subtle mass shift, may co-elute with the target.
• Residual protecting groups — fragments of the protecting groups used during synthesis that didn't fully cleave. Usually low-area peaks at distinctive retention times.
• Counter-ion / TFA artifacts — peaks from the trifluoroacetic acid used in synthesis or HPLC purification. Distinctive UV absorbance, generally identifiable.

A practiced eye reading a chromatogram can often guess the impurity origin from the peak's position relative to the target. Deeper peak-by-peak interpretation is its own topic, covered in common HPLC artifacts and what impurity peaks mean.

How should a real HPLC report look?

A complete HPLC purity report on a Certificate of Analysis is multi-page documentation, not a single number. The chromatogram is the headline; the parameters, integration results, system suitability data, and analyst attribution are what make the chromatogram interpretable.

• The chromatogram itself — a plot, not just a number. The plot is the evidence the test was run.
• Method parameters — column type and dimensions, mobile phase composition, gradient profile, flow rate, detection wavelength, injection volume.
• Integration results — target peak retention time, target peak area, total area, calculated purity. Some reports list the area of every peak above the integration threshold; better reports do.
• System suitability data — confirms the HPLC system was performing within spec at the time of analysis. USP <621> covers system-suitability requirements explicitly.
• Analyst and date — the person who ran the test and when.

A "report" that is just a number with no chromatogram is not a report. It is a claim. Real reports are bulky — multi-page documents with figures, parameter tables, and integration printouts.

How does Nexara connect testing to the published number?

Nexara requires ≥99% HPLC purity for any peptide to ship. Batches below threshold are not sold, the chromatogram for each batch is included on the Certificate of Analysis, and the field-by-field walkthrough of the COA explains how to interpret each result. Lyophilized form and proper cold-chain handling preserve the chromatographic integrity from production through transit, and our research compliance position covers what we deliberately do not publish — including reconstitution calculators and dose-conversion math.

Sources and further reading

• USP <621> Chromatography — the pharmacopeial reference for HPLC system suitability requirements, peak resolution criteria, and reporting standards.
• USP <1086> Impurities in Drug Substances and Drug Products — guidance on classifying and reporting impurity profiles in synthesized compounds.
• FDA Guidance for Industry: Q3A(R2) Impurities in New Drug Substances — the ICH-aligned framework for impurity identification thresholds and reporting structure.
• Snyder, Kirkland, & Dolan — Introduction to Modern Liquid Chromatography (Wiley, 3rd ed.) — the standard graduate-level reference text on HPLC method development and interpretation.